German Federal Patent Court denies request for preliminary grant of a compulsory license – Where do we go from here?

http://www.twobirds.com/en/patenthub/shared/articles/2019/germany/german-federal-patent-court-denies-request-for-preliminary-grant-of-compulsory-license

Sanofi sought a compulsory licence for the distribution of its high cholesterol drug Praluent® but this was dismissed in preliminary proceedings (docket no: 3 LiQ 1/18).

07 February 2019

New Decision: Higher Regional Court Düsseldorf on Second Medical Use Patents

http://www.twobirds.com/en/patenthub/shared/articles/2019/germany/new-decision-higher-regional-court-dusseldorf-on-second-medical-use-patents

In 2017 the Higher Regional Court Düsseldorf first iterated new liability criteria with respect to Second Medical Use Patents (cf. decision Östrogenblocker of May 5, 2017, docket no. I-2 W 6/17).

14 January 2019

Patents: SPCs: combined medical device and medicinal product

http://www.twobirds.com/en/patenthub/shared/articles/2018/global/patents-spcs-combined-medical-device-and-medicinal-product

This decision follows the recent trend for the ECJ to give more straightforward interpretations of the SPC Regulation, providing certainty for users of the system.

05 December 2018

Supreme Court defines plausibility in the context of sufficiency

http://www.twobirds.com/en/patenthub/shared/articles/2018/uk/supreme-court-defines-plausibility-in-the-context-of-sufficiency

A majority postulates a new "outward presentation test" to deal with the infringement of second medical use patents.

15 November 2018

Arrow still flies

http://www.twobirds.com/en/patenthub/shared/articles/2018/uk/arrow-still-flies

During 2016 and 2017 the complex litigation about part of AbbVie's patent portfolio protecting its Humira/adalimumab product drew attention in part because of the granting of a so-called Arrow declaration.

02 July 2018